Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | SLC15A1 | P46059 | 2/20 | 0.46 |
| ▸ | LTA4H | P09960 | 2/20 | 0.46 |
| ▸ | LAP3 | P28838 | 1/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.45 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ALPI | P09923 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL25224887 | 1.00 | ALDH1A1 (0.53) | ALDH1A1IDO1SLC1A1KMT2AMAPK1 | |
| SCHEMBL6118400 | 1.00 | ALDH1A1 (0.53) | ALDH1A1IDO1SLC1A1KMT2AMAPK1 | |
| Hydrochloric Acid SCHEMBL4704977 | 1.00 | ALDH1A1 (0.53) | ALDH1A1IDO1SLC1A1KMT2AMAPK1 | |
| Hydrochloric Acid SCHEMBL4704980 | 1.00 | ALDH1A1 (0.53) | ALDH1A1IDO1SLC1A1KMT2AMAPK1 | |
| SCHEMBL6119410 | 1.00 | ALDH1A1 (0.53) | ALDH1A1IDO1SLC1A1KMT2AMAPK1 | |
| Hydrochloric Acid SCHEMBL11024444 | 0.87 | SLC1A1 (0.59) | ALDH1A1IDO1SLC1A1KMT2AMAPK1 | |
| Hydrochloric Acid SCHEMBL29556904 | 0.87 | SLC1A1 (0.59) | ALDH1A1IDO1SLC1A1KMT2AMAPK1 | |
| Hydrochloric Acid SCHEMBL20996762 | 0.87 | SLC1A1 (0.59) | ALDH1A1IDO1SLC1A1KMT2AMAPK1 | |
| SCHEMBL23947614 | 0.86 | ALDH1A1 (0.52) | ALDH1A1IDO1SLC1A1KMT2AMAPK1 | |
| SCHEMBL7419155 | 0.85 | SLC1A1 (0.60) | ALDH1A1IDO1SLC1A1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464321-B1 | PROTEASOME INHIBITORS | MAX PLANCK GESELLSCHAFT (DE) | 2023-01-25 | — | — | EP | disclosed |
| US-11345724-B2 | Proteasome inhibitors | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-05-31 | — | — | US | disclosed |
| US-10829470-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200325171-A1 | PROTEASOME INHIBITORS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2020-10-15 | — | — | US | disclosed |
| US-10787482-B2 | Epoxyketone compounds for enzyme inhibition | Centrax International Inc. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20200087343-A1 | EPOXYKETONE COMPOUNDS FOR ENZYME INHIBITION | CENTRAX INTERNATIONAL, INC. (US) | 2020-03-19 | — | — | US | disclosed |
| US-20190112287-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2019-04-18 | — | — | US | disclosed |
| WO-2018112078-A1 | GASTRO-RETENTIVE MODIFIED RELEASE DOSAGE FORMS FOR OPROZOMIB AND PROCESS TO MAKE THEREOF | AMGEN INC. (US) | 2018-06-21 | — | — | WO | disclosed |
| US-20180161279-A1 | GASTRO-RETENTIVE MODIFIED RELEASE DOSAGE FORMS FOR OPROZOMIB AND PROCESS TO MAKE THEREOF | AMGEN INC. | 2018-06-14 | — | — | US | disclosed |
| WO-2018057453-A1 | IMMEDIATE RELEASE FORMULATIONS FOR OPROZOMIB | AMGEN INC. (US) | 2018-03-29 | — | — | WO | disclosed |
| US-20120088903-A1 | CRYSTALLINE TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. | 2012-04-12 | — | — | US | disclosed |
| US-20120077855-A1 | CRYSTALLINE TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. | 2012-03-29 | — | — | US | disclosed |
| US-20100240903-A1 | CRYSTALLINE TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-7687456-B2 | Compounds for enzyme inhibition | PROTEOLIX, INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20090203698-A1 | Compounds for Enzyme Inhibition | PROTEOLIX, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| EP-1567489-B1 | PYRROLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF THROMBIN AND FACTOR XA | GLAXO GROUP LTD (GB) | 2008-07-23 | — | — | EP | disclosed |
| US-20070105786-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2007-05-10 | — | — | US | disclosed |
| US-20060166985-A1 | Pyrrolydin-2-one derivatives as inhibitors of thrombin and factor xa | GLAXO GROUP LIMITED (GB) | 2006-07-27 | — | — | US | disclosed |
| EP-1567489-A1 | PYRROLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF THROMBIN AND FACTOR XA | GLAXO GROUP LIMITED (GB) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004052851-A1 | PYRROLYDIN-2-ONE DERIVATIVES AS INHIBITORS OF THROMBIN AND FACTOR XA | GLAXO GROUP LIMITED (GB) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325171-A1 | PROTEASOME INHIBITORS | PSMB1, PSMB2, PSMB5 | ALDH1A1 3387/4885IDO1 3441/4885SLC1A1 3481/4885 |
| US-10787482-B2 | Epoxyketone compounds for enzyme inhibition | PSMD10, PSMC1, PSMB10 | ALDH1A1 1707/4885IDO1 3721/4885SLC1A1 4049/4885 |
| US-20070105786-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | ANPEP, PSMB1, PSMB3 | ALDH1A1 3650/4885IDO1 2072/4885SLC1A1 4318/4885 |
| US-20060166985-A1 | Pyrrolydin-2-one derivatives as inhibitors of thrombin and factor xa | TFPI, TFPI2, SERPINC1 | ALDH1A1 3827/4885IDO1 547/4885SLC1A1 4830/4885 |
| US-20180161279-A1 | GASTRO-RETENTIVE MODIFIED RELEASE DOSAGE FORMS FOR OPROZOMIB AND PROCESS TO MAKE THEREOF | GIPR, OPRL1, MLNR | ALDH1A1 3729/4885IDO1 3930/4885SLC1A1 916/4885 |
| US-10829470-B2 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | ALDH1A1 1089/4885IDO1 2927/4885SLC1A1 4471/4885 |
| US-11345724-B2 | Proteasome inhibitors | PSMB1, PSMB2, PSMB5 | ALDH1A1 3319/4885IDO1 3436/4885SLC1A1 3469/4885 |
| US-20090203698-A1 | Compounds for Enzyme Inhibition | ANPEP, HPN, DNPEP | ALDH1A1 3041/4885IDO1 1172/4885SLC1A1 3694/4885 |
| US-20100240903-A1 | CRYSTALLINE TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | PREP, CTSC, PEPD | ALDH1A1 2956/4885IDO1 2481/4885SLC1A1 3615/4885 |
| US-20190112287-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | ALDH1A1 1089/4885IDO1 2927/4885SLC1A1 4471/4885 |
| US-20200087343-A1 | EPOXYKETONE COMPOUNDS FOR ENZYME INHIBITION | PSMD10, PSMC1, PSMB10 | ALDH1A1 1707/4885IDO1 3721/4885SLC1A1 4049/4885 |
| US-20120077855-A1 | CRYSTALLINE TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | CTSC, PEPD, PREP | ALDH1A1 3205/4885IDO1 2091/4885SLC1A1 3789/4885 |
| US-20120088903-A1 | CRYSTALLINE TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | PREP, CTSC, PEPD | ALDH1A1 2956/4885IDO1 2481/4885SLC1A1 3615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.